Published in Br J Cancer on October 31, 2005
Critical role of lipid raft redox signaling platforms in endostatin-induced coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol (2007) 1.29
A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One (2012) 1.12
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clin Cancer Res (2008) 0.89
Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One (2010) 0.86
Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Cancer Biol Ther (2011) 0.86
Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol (2006) 0.85
Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function. Matrix Biol (2010) 0.84
Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells. J Transl Med (2013) 0.83
Type I collagen gene suppresses tumor growth and invasion of malignant human glioma cells. Cancer Cell Int (2007) 0.82
Retinal Changes Induced by Epiretinal Tangential Forces. J Ophthalmol (2015) 0.80
Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors. J Cancer Sci Ther (2013) 0.78
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer (2003) 6.65
Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med (2003) 4.77
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell (2003) 3.68
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet (2002) 3.35
Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88
Integrins: roles in cancer development and as treatment targets. Br J Cancer (2004) 2.76
Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A (2003) 2.28
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem (2002) 1.98
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer (2002) 1.65
Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol (2004) 1.61
Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res (2001) 1.55
Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol (2002) 1.54
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51
Cell surface glypicans are low-affinity endostatin receptors. Mol Cell (2001) 1.51
Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst (2004) 1.49
Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem (2001) 1.46
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2002) 1.41
Physiological role of collagen XVIII and endostatin. FASEB J (2005) 1.40
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res (2003) 1.35
Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol (2002) 1.34
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2003) 1.33
Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem (2005) 1.31
Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem (2003) 1.19
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol (2002) 1.18
Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol (1985) 1.14
High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet (2001) 1.13
A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res (2005) 1.10
Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem (2001) 1.08
Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res (2004) 1.04
Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett (2002) 0.95
Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res (2003) 0.89
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res (2004) 0.89
Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol (2003) 0.88
The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res (2004) 0.87
Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res (2002) 0.85
Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer (2004) 0.83
Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer (2002) 0.82
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer (2007) 2.98
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol (2003) 1.61
Intra-tumoural microvessel density in human solid tumours. Br J Cancer (2002) 1.60
Carcinosarcoma of the ovary. Br J Cancer (2003) 1.41
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer (2011) 1.40
The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) (2003) 1.23
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol (2000) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer (2000) 1.08
Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis (2007) 1.06
Antiangiogenic drugs in ovarian cancer. Br J Cancer (2008) 1.06
Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer (2003) 1.00
Quantitative angiogenesis assays in vivo--a review. Angiogenesis (2004) 0.99
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer (2005) 0.98
Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer (2007) 0.97
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol (2010) 0.97
The clinical development of the bryostatins. Anticancer Drugs (2002) 0.95
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol (2010) 0.93
p53 and related proteins in epithelial ovarian cancer. Eur J Cancer (2000) 0.88
The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer (1998) 0.88
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 0.88
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol (2010) 0.87
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res (2007) 0.87
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer (2001) 0.86
An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Br J Cancer (1999) 0.85
VEGF antagonists. Expert Opin Biol Ther (2001) 0.83
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer (2003) 0.82
Resistance to anti-VEGF agents. Curr Pharm Des (2004) 0.82
Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. Clin Oncol (R Coll Radiol) (2005) 0.81
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Ann Oncol (2000) 0.79
Weekly paclitaxel in the treatment of recurrent ovarian carcinoma. Eur J Gynaecol Oncol (2007) 0.79
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer (2006) 0.78
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol (2007) 0.77
Cross-visit tumor sub-segmentation and registration with outlier rejection for dynamic contrast-enhanced MRI time series data. Med Image Comput Comput Assist Interv (2010) 0.77
The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol (2006) 0.77
Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol (2000) 0.77
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer (2010) 0.77
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res (2005) 0.76
Oral melphalan as a treatment for platinum-resistant ovarian cancer. Br J Cancer (2003) 0.75
Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer (2002) 0.75
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol Oncol (2004) 0.75
Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. J Cancer Res Clin Oncol (2005) 0.75
The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. Clin Oncol (R Coll Radiol) (2007) 0.75
Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer (2006) 0.75